Pleiotropic effects of ß-adrenoblockers in the therapy of cardiovascular diseases: Effect on lipid peroxidation, coagulological and vasomotor properties of endothelium and evolution of atherosclerosis

Kardiologiya

Volumn 49, Issue 6, 2009, Pages 61-66

  Sitnikova, M Y U ^a   Ivanov, S C ^a   Khmelnitskaya, K A ^a  

^a ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

Author keywords

adrenoblockers; Carotid artery intima media complex.; Coagulation parameters; Endothelial function; Lipid peroxidation

Indexed keywords

ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; HEMOSTASIS; HUMAN; LIPID PEROXIDATION; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; ANTIOXIDANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS;

EID: 70349309677     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Jackso J.D., Muhlestein J. B., Bunch T. J. et al. Intermountain Heart Collaborative Study (IHCS) Group. Beta-blockers reduce the incidence of clinical restenosis: prospective study of4840 patients undergoing percutaneous coronary revascularization. Clini Investig Am Heart J 2003; 145:875-881. (Pubitemid 36570959)
2. Lee S.-H., Yoon S.-B., Cho J.-R et al. The Effects of Different ß-Blockers on Left-Ventricular Volume and Function After Primary Coronary Stenting in Acute Myocardial Infarction. Angiology 2009; 59: 676-681.
3. Wang R., Miura T., Harada N. etal. Pleiotrope Effects of the -Adrenoceptor Blocker Carvedilol on Calcium Regulation during Oxidative Stress-Induced Apoptosis in Cardiomyocytes. JPET 2006; 318: 45-52.
4. Yasunari K, Maeda K, Nakamura M. et al. Effects of Carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116:460-465. (Pubitemid 38388615)
5. Fahlbusch S.A., Tslkas D., Mehls C, Gutzkl F.M. Effects of Carvedilol on oxidative stress in human endothelial cells and healthy volunteers. Eur J Clin Pharmacol 2004;60:83-88. (Pubitemid 38656126)
6. Kukin M.L., Kaiman J., Chamey R.H. et al. Prospective, randomized comparison of effect of long-term treatment with metoproloi or Carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-2651. (Pubitemid 29237451)
7. Metra M., Giubbini R., Nodari S. et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus Carvedilol. Circulation 2000;102:546-551. (Pubitemid 30642529)
8. Beanlands R.S.B., Nahmias C, Gordon E. et al. The Effects of ßl-Blockade on Oxidative Metabolism and the Metabolic Cost of Ventricular Work in Patients With Left Ventricular Dysfunction. Circulation 2000; 102: 2070.
9. Mehta J.L., Romeo F., Li D., Shi M. Epinephrine induces free radical release und upregulates endogenous superoxide dismutase gene and protein expression in human coronary artery endothelial cells. J Am Coll Card 2000; 35( Suppl.A): 173.
10. de Groot AA., Mathy M.J., van Zwteten P.A., Peters S.L. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148-153. (Pubitemid 38032077)
11. Larsson P. T., Wlman B., Olsson G. et al. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 1990;63:482-487. (Pubitemid 20214730)
12. Teger-Nibson A.C., Larsson P.T., Hjemdahl P., Olsson G. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease: potential effects of ß-blockade. Circulation 1991; 84 ( Suppl.): VI72-VI77.
13. Wlnther K., Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and ß-adrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18 ( Suppl. 9): S41-S44.
14. Seljeflot I., Amesen H., Andersen P. et al. Effects of doxazosin and atenolol on endothelin-1 and von Willebrand factor in hypertensive middle-aged men. Eur Heart J 1999; 20: 76.
15. Small M., Douglas J.T., Aherne G.W. et al. Effects of the nonselective beta-adrenoreceptor blocking agent, Carvedilol, on platelet function, blood coagulation and viscosity. Thromb Res 1982;25:351-360. (Pubitemid 12149200)
16. Okrucka A., Pechan J., Kratochvílova H. Effect of long-term Celiprolol therapy on hacmostasis in essential hypertension. J Hum Hypertens 1995; 9: 773-776.
17. Jlmenez A.H., Tofler G.H., Chen X. et al. Effects ofnadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension. Am J Cardiol 1993;72:47-52. (Pubitemid 23184361)
18. Fogari R., Zoppl A., Malamarl GD. et al. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995; 39: 471-476.
19. Gibbs CR., Blann A.D., Watson R.D.S. et al. Effects of treatment with ACE inhibitors and beta-blockers on haemorheological, endothelial and platelet markers in patients with chronic heart failure. Eur Heart J 2000; 21: 406.
20. Moriau M., Noel H., Masure R. Effects of alpha and beta receptor stimulating and blocking agents on experimental disseminated intravascular coagulation. Thromb Diath Haemorrh 1974; 32: 157-170.
21. Sayer J. W., Gutterldge C, Syndercombe-Court D. et al. Orcadian activity of the endogenous fibrinolytic system in stable coronary artery disease: Effect of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1998;32:1962-1968. (Pubitemid 29010462)
22. Held C, Hjemdahl P., Rehnqvlst N. et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the angina prognosis study in Stockholm. Circulation 1997;95:2380-2386. (Pubitemid 27224732)
23. Newby D.E., Wright R.A., Dawson P. et al. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 1998;38:485-492. (Pubitemid 28294167)
24. Sinisab J., Syrjala M., Mattila K.J. et al. Endothelial release of tissue-type plasminogen activator and ischemia-induced vasodilatation are linked in patients with coronary heart disease. Blood Coagul Fibrinolysis 1999;10:181-187. (Pubitemid 29356311)
25. Pettersson K, Bejne B., Bjõrk H. et al. Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via ß,-adrenoceptor activation. Circ Res 1990;67:1027-1034. (Pubitemid 20315034)
26. Gonta A., Dan G., Stanescu C, Vintila M. Improvement in vascular endothelial functtion in patients with heart failure treated with ß-blockers. Eur Heart J 1999; 20: 375.
27. Östlund-Lindqvist A., LindqyistP., Bräutigam J. etal. Effect of metoprolol on diet-induced atherosclerosis in rabbits. Arteriosclerosis 1988;8:40-45. (Pubitemid 18049174)
28. Hedblad B., Wikstrand J., Janzon L. et al. Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness Main Results From the ß-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721-1726. (Pubitemid 32291407)
29. Wiklund O., Hulthe J., Wikstrand J. et al. Effect of Controlled Release/ Extended Release Metoprolol on Carotid Intima-Media Thickness in Patients With Hypercholesterolemia. A 3-Year Randomized Study. Stroke 2002;33;572-577. (Pubitemid 34123409)
30. Chopra V., Plaisance B., Cavusogtu E. et al. Perioperative Beta-blockers for Major Noncardiac Surgery: Primum Non Nocere. Am J Med 2009; 122: 203-312.